The main objectives of the current study were to compare HER2 results between a novel HER2 test (HERmark) and routine HER2 tests (IHC and FISH), and to correlate HER2 results by various HER2 testing methods with overall survival of breast cancer patients from a multicenter Collaborative Biomarker Study. This evidence concerns the gene ERBB2 and breast cancer.